Treatment of mental illness via administration of buntanetap and analogues thereof

A neuropsychotic pharmaceutical composition, comprising:

• (i) a therapeutically effective amount of a compound selected from the group consisting of Formula (I), Formula (II) and Formula (III):
• wherein,
• in Formula (I) and Formula (II), R1 and R2 are, independently, hydrogen, branched or straight chain C1-C8 alkyl, substituted or unsubstituted aryl, heteroaryl, or aralkyl;
• R3 is branched or straight chain C1-C4 alkyl or heteroalkyl or C4-C8 alkyl or heteroalkyl, or substituted or unsubstituted aryl;
• X and Y are, independently, O, S, alkyl, hydrocarbon moiety, C(H)R4, or NR5, wherein R4 and R5 are, independently, hydrogen, oxygen, branched or straight chain C1-C8 alkyl, C2-C8 alkenyl or C2-C8 alkynyl, aralkyl, or substituted or unsubstituted aryl;
• and
• R6 is hydrogen;
• C1-C8 alkyl, C1-C8 alkenyl, C2-C8 alkynyl, aralkyl, or substituted or unsubstituted aryl, or (CH2)nR7, where R7 is hydroxy, alkoxy, cyano, ester, carboxylic acid, substituted or unsubstituted amino, and n is from 1 to 4;
• wherein,
• in Formula (III), R1 and R2 are, independently, hydrogen, branched or straight chain C1-C8 alkyl, substituted or unsubstituted aryl, heteroaryl, or aralkyl;
• R3 is branched or straight chain C1-C4 alkyl or heteroalkyl or C4-C8 alkyl or heteroalkyl, or substituted or unsubstituted aryl;
• X is NR5, wherein R5 is C2-8 alkenyl, C2-8 alkynyl, or aralkyl;
• Y is selected from C(H)R4 or NR5, wherein R4 and R5 are, independently, hydrogen, branched or straight chain C1-8 alkyl or heteroalkyl, alkenyl, or C2-C8 alkynyl, aralkyl;
• and
• wherein the compound having the Formula (I), Formula (II) or Formula (III) is the substantially pure (−)-enantiomer, the substantially pure (+)-enantiomer, or a racemic mixture of the (−)-enantiomer and (+)-enantiomers or a pharmaceutically acceptable salt thereof;
• (ii) an effective amount of compound selected from the group consisting of an antipsychotic agent, an antidepressant agent, a hallucinogenic agent, and pharmaceutically acceptable salts thereof;
• and at least one pharmaceutically acceptable excipient.